This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The Firm is investigating testosterone treatment lawsuits on behalf of men who suffered serious cardiovascular events, including heart attacks, strokes, deep vein thrombosis, and pulmonary embolism, due to the use of AndroGel and other low testosterone therapies.
New York, NY (PRWEB) July 10, 2014
Testosterone lawsuits (http://www.testosteronelawsuitclaims.com/) have begun to progress in both state and federal courts, Bernstein Liebhard LLP reports. According to a request filed in the U.S. District Court, Northern District of Illinois, AbbVie and Abbott Laboratories have asked the Court to consider ways in which the federal multidistrict litigation can be coordinated with claims pending in various state courts, as the companies are named defendants in a number of AndroGel lawsuits filed on both the state and federal level. The Court is expected to discuss the drug makers request today, when it convenes the first status conference for the federal testosterone litigation. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Our Firm is evaluating a number of claims on behalf of men who allegedly suffered life-threatening cardiovascular events due to the use of AndroGel and other low testosterone therapies. We are pleased that the litigation involving testosterone lawsuits is moving forward, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm offers free legal reviews to men who suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other heart injuries allegedly due to low testosterone treatments.
Testosterone Treatment Lawsuit
According to court documents, nearly 100 testosterone treatment lawsuits are pending in the litigation underway in the Northern District of Illinois. While the majority of the claims involve AndroGel, a number of cases have been filed by men who were allegedly harmed by other medications, including Axiron, Testim and AndroGel. Among other things, all of these lawsuits similarly allege that the manufacturers of testosterone replacement therapies failed to provide adequate warnings regarding the cardiovascular risks associated with their products.
The litigation surrounding low testosterone therapy has been growing since January, when the U.S. Food & Drug Administration (FDA) announced it was reviewing the heart risks associated with this class of medication. The FDA was prompted to act by the publication of two studies which indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were undergoing low testosterone therapy.
In a second alert published on June 20th, the FDA announced that the labeling for all approved testosterone drugs would be updated to include information about the potential for venous blood clots, including deep vein thrombosis and pulmonary embolism. The agency did acknowledge that the product labels for the medications already included information about venous blood clots that may occur due to the development of polycythemia. However, the FDA deemed the changes necessary after it received a number of reports detailing the development of venous blood clots in testosterone patients unrelated to that condition.*
Alleged victims of cardiovascular injuries associated with the use of AndroGel and other testosterone therapies may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury-related damages. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm, FDA, June 20, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/testosterone-lawsuit/androgel-lawsuit/prweb12009644.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.